Edition:
United Kingdom

Abbvie Announces First Regulatory Approval Of SKYRIZI


Tuesday, 26 Mar 2019 

March 26 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES FIRST REGULATORY APPROVAL OF SKYRIZI™ (RISANKIZUMAB) FOR THE TREATMENT OF PLAQUE PSORIASIS, GENERALIZED PUSTULAR PSORIASIS AND ERYTHRODERMIC PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN.ABBVIE INC SAYS JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFARE HAS APPROVED SKYRIZI AN INTERLEUKIN-23 INHIBITOR.